In short
Clinical trials are investigating Alx148 in people with higher risk myelodysplastic syndrome, including patients who have not been treated before. These studies are looking at safety, tolerability, and how well the treatment works, especially when Alx148 is given with azacitidine.
Key points
- Clinical trials of Alx148 are focused on higher risk myelodysplastic syndrome, a serious blood disorder. The main study is a Phase 1/2 trial testing Alx148 with azacitidine in adults, including people who had not been treated before and some with relapsed or refractory disease. Phase 1 looks at safety, tolerability, and dose finding, while the phase 2 part looks at complete response rate. The study also tracks adverse events and dose-limiting toxicities. The trial was completed and enrolled 6 people. The phase 2 part compares the combination against azacitidine alone in previously untreated higher risk MDS.
Trial overview
The main study in the data is NCT04417517, a Phase 1/2 study of Alx148 with azacitidine in people with higher risk myelodysplastic syndrome (MDS). The study was designed to look first at safety and dose finding, and then at how well the treatment worked in patients with previously untreated higher risk MDS.
Who was studied
This trial included adults with higher risk MDS, which means a form of bone marrow disease with a greater chance of serious progression. The brief summary says the Phase 1 part included adult patients with relapsed or refractory MDS, as well as previously untreated higher risk MDS, while the Phase 2 part focused on previously untreated higher risk MDS with an IPSS-R score above 3.5.
Relapsed means the disease came back after improvement, and refractory means it did not respond well to treatment. Previously untreated means patients had not yet received treatment for their disease.
What was tested
The study tested Alx148 in combination with azacitidine, and both drugs were given by intravenous use in the trial record. The Phase 2 part compared the combination of Alx148 at the recommended Phase 2 dose with azacitidine alone.
The trial was not only asking whether the treatment might help, but also whether it could be given safely in this patient group. In simple terms, the study was trying to find the best balance between possible benefit and acceptable safety.
Study phases and endpoints
Phase 1 focused on safety, tolerability, and finding the recommended Phase 2 dose, also called RP2D. The dose escalation part looked for dose-limiting toxicities, which are side effects serious enough to limit treatment at a certain dose.
The dose expansion part measured adverse events, meaning any medical problems that happened during treatment, and recorded their type, frequency, severity, timing, seriousness, and relationship to the study therapy. These details help researchers understand how the treatment behaves in more patients.
The Phase 2 part measured complete response rate (CRR), which is the share of patients who reached a complete response by the study’s response rules. The study used modified IWG 2006 response criteria for MDS, and the final analysis was planned after the last patient finished 6 treatment cycles or was ready to be assessed for response.
Trial status and size
The trial status is listed as Completed. The enrollment was small, with 6 participants in the record provided. Because this was an early-phase study, the main goal was to learn about safety and the right dose before larger studies could be done.
Key patient terms
- Interventional study: a trial where researchers give a treatment and then measure what happens.
- Intravenous use: medicine given through a vein.
- Response criteria: the rules used to decide whether the disease improved.
- Complete response: a strong improvement defined by the study’s rules.
- IPSS-R score: a risk score used to show how serious MDS is.